Compare PRAX & ALSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | ALSN |
|---|---|---|
| Founded | 2015 | 1915 |
| Country | United States | United States |
| Employees | N/A | 4000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.9B |
| IPO Year | 2020 | 2011 |
| Metric | PRAX | ALSN |
|---|---|---|
| Price | $337.29 | $130.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 7 |
| Target Price | ★ $572.13 | $117.57 |
| AVG Volume (30 Days) | 326.2K | ★ 677.9K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 7.33 |
| Revenue | N/A | ★ $3,010,000,000.00 |
| Revenue This Year | N/A | $94.98 |
| Revenue Next Year | $7,758.26 | $5.30 |
| P/E Ratio | ★ N/A | $17.94 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.89 | $76.01 |
| 52 Week High | $354.87 | $137.62 |
| Indicator | PRAX | ALSN |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 54.54 |
| Support Level | $282.49 | $110.01 |
| Resistance Level | $353.83 | $137.62 |
| Average True Range (ATR) | 18.75 | 3.50 |
| MACD | -0.96 | -0.41 |
| Stochastic Oscillator | 69.67 | 41.46 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.